In an effort to appropriately and more accurately evaluate the progress of studies during continuing IRB review, the PPHS will begin asking questions regarding the banking and use of banked specimens. The current HRP-212 Continuation Form (or Ideate continuation submission) does not ask questions about banking. We recognized a need for this information and are improving the review process by requesting answers to these important questions at the time of review.

If you have a protocol or a study that involves collecting and storing specimens for future use (banking samples), please include a memo addressing the following questions with appropriate continuation submissions. For Ideate submissions, upload this memo to the Attachments tab.

Since last continuing review and overall to date, please address the followir use of specimens for this study:

1. How many individual subjects agreed to have samples banked?
2. Have any samples been used or shared with other researchers?
   a) If yes, provide project title, PI, location and date.
3. How many samples does the study team have on hand that are being stored?
   Note: Please do not include samples that are simply being held for an original project but for which no future use is planned.
   a) If not, provide details.
4. If the approved consent allows/allows subjects options to limit future use of samples (to the purpose of the original study) does the study team have a consolidated plan to identify and select for all the samples?
   a) If not, provide details.
5. Have any stored samples been shared with other researchers, other than the purpose of this project?
   a) If yes, provide details.
a) If yes, provide project title, PI, location, numbers of samples and date.

6. Has the study team used any stored samples for purposes other than cor in this protocol?
   a) If yes, provide project title, numbers of samples used to date.

7. Have any stored samples been withdrawn for any reason?
   a) If yes, please explain how many and why?

For questions, please call the PPHS office at 212-824-8200.

Thank you for your attention to this update.